Intraperitoneal Hyperthermic Perfusion Chemotherapy for Postoperative Advanced Gastric Cancer: A Systematic Review
LI Zheng,YANG Ke-hu,MI Deng-hai,TIAN Jin-hui,LIU Xiao-guang
DOI: https://doi.org/10.3969/j.issn.1672-2531.2011.12.011
2011-01-01
Abstract:Objective To evaluate the e ectiveness and safety of postoperative intraperitoneal hyperthermic per-fusion chemotherapy(IHPC) for advanced gastric cancer,so as to provide references for clinical practice and study.Methods e following databases including e Cochrane Library,PubMed,EMbase,CBM,CNKI,VIP and WanFang were searched on computer,and other searches were also performed to collect all relevant randomized controlled trials(RCTs) on postoperative IHPC versus intravenous chemotherapy alone(IC) for advanced gastric cancer.e quality of the included studies was assessed according to Cochrane Handbook 5.1 for Systematic Review,and Meta-analysis was conducted by using RevMan 5.1 so ware.Results A total of 18 RCTs involving 2299 patients were included.e results of meta-analyses showed that: a) E cacy evaluation: ere were signi cant di erences between the IHPC group and the IC group in 1-,2-,3-,and 5-year survival rate,3-and 5-year recurrence rate,and 3-and 5-year distant metastasis rate;the OR value and 95%CI were 1.88(1.49,2.39),2.45(1.64,3.67),2.29(1.92,2.73),2.17(1.70,2.76),0.39(0.29,0.52),0.54(0.40,0.72),0.55(0.38,0.78),0.58(0.42,0.81),respectively;b) Safety evaluation: ere were signi cant di erences between the IHPC group and the IC group in the incidence of abdominal pain,abdominal distension,nausea and vomiting;the OR value and 95%CI were 2.20(1.58,3.07),7.00(2.67,18.36),0.65(0.45,0.95),respectively.But there were no signi cant dif-ferences between the IHPC group and the IC group in the incidence of alopecia,ileus,bone marrow inhibition,and hepat-ic lesion.Conclusion Compared with IC,postoperative IHPC+IC can improve survival rate and reduce the recurrence and distant metastasis rate;additionally,it is safe and feasible,so it is recommended that the detailed condition of patients should be taken into consideration when the postoperative IHPC+IC therapy is applied to clinic.